Endurance Wealth Management’s C4 Therapeutics CCCC Stock Holding History

Endurance Wealth Management’s Portfolio CCCC Stock Details CCCC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	$15K	Hold	1,850	–	–	﹤0.01%	457
2023 Q1	$0	Hold	1,850	–	–	﹤0.01%	643
2022 Q4	$11K	Hold	1,850	–	–	﹤0.01%	471
2022 Q3	$16K	Hold	1,850	–	–	﹤0.01%	431
2022 Q2	$14K	Buy	1,850 +1,500	+429%	+$13.2K	﹤0.01%	452
2022 Q1	$8K	Hold	350	–	–	﹤0.01%	529
2021 Q4	$11K	Hold	350	–	–	﹤0.01%	498
2021 Q3	$12K	Hold	350	–	–	﹤0.01%	500
2021 Q2	$15K	Hold	350	–	–	﹤0.01%	490
2021 Q1	$13K	Buy	+350	New	+$13.9K	﹤0.01%	502

Other funds holding CCCC

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

ACM

Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return

Endurance Wealth Management's CCCC Position: Q2 2023 in Review

Endurance Wealth Management held its C4 Therapeutics (CCCC) position steady in Q2 2023 at 1,850 shares worth $15K. The position accounts for ﹤0.01% of the portfolio, ranked #457.

Endurance Wealth Management first reported a position in CCCC in Q1 2021 and has held it in 10 quarters since. The position peaked at $16K in Q3 2022. 100 funds tracked by Wall St. Rank hold CCCC as of Q2 2023.

Endurance Wealth Management held 1,850 shares of C4 Therapeutics worth $15K as of Q2 2023.
Endurance Wealth Management left its C4 Therapeutics share count unchanged in Q2 2023.
C4 Therapeutics made up ﹤0.01% of Endurance Wealth Management's portfolio in Q2 2023, its #457 holding.
Endurance Wealth Management first reported a position in C4 Therapeutics in Q1 2021 and has held it in 10 quarters since.
Endurance Wealth Management's C4 Therapeutics position peaked at $16K in Q3 2022.
100 funds tracked by Wall St. Rank held C4 Therapeutics as of Q2 2023.

Based on Endurance Wealth Management's 13F filing for Q2 2023, filed 9 Aug 2023.